• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.

作者信息

Hoff Fieke W, Huang Ying, Welkie Rina Li, Swords Ronan T, Traer Elie, Stein Eytan M, Lin Tara L, Patel Prapti A, Collins Robert H, Baer Maria R, Duong Vu H, Blum William G, Arellano Martha L, Stock Wendy, Odenike Olatoyosi, Redner Robert L, Kovacsovics Tibor, Deininger Michael W, Zeidner Joshua F, Olin Rebecca L, Smith Catherine C, Foran James M, Schiller Gary J, Curran Emily K, Koenig Kristin L, Heerema Nyla A, Chen Timothy, Martycz Molly, Stefanos Mona, Marcus Sonja G, Rosenberg Leonard, Druker Brian J, Levine Ross L, Burd Amy, Yocum Ashley O, Borate Uma M, Mims Alice S, Byrd John C, Madanat Yazan F

机构信息

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Department of Medicine, The Ohio State University, Columbus, OH, USA.

出版信息

Blood Cancer J. 2025 Apr 3;15(1):55. doi: 10.1038/s41408-025-01258-0.

DOI:10.1038/s41408-025-01258-0
PMID:40180903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11968959/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8060/11968959/5d3404d6b2bd/41408_2025_1258_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8060/11968959/5d3404d6b2bd/41408_2025_1258_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8060/11968959/5d3404d6b2bd/41408_2025_1258_Fig1_HTML.jpg

相似文献

1
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.60岁及以上新诊断急性髓系白血病患者的分子特征：来自Beat AML临床试验的报告
Blood Cancer J. 2025 Apr 3;15(1):55. doi: 10.1038/s41408-025-01258-0.
2
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.阿糖胞苷的药物基因组学与急性髓系白血病儿童及青年患者的预后
JAMA Netw Open. 2025 Jun 2;8(6):e2516296. doi: 10.1001/jamanetworkopen.2025.16296.
3
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.基于低强度治疗的新诊断 AML 老年患者的 Beat-AML 2024 ELN 精细化风险分层。
Blood Adv. 2024 Oct 22;8(20):5297-5305. doi: 10.1182/bloodadvances.2024013685.
4
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.一项针对年龄≥60岁的未经治疗的急性髓系白血病患者，使用TP-0903和地西他滨靶向突变型TP53和/或复杂核型的1b/2期研究。
Cancer Res Commun. 2025 Jul 1;5(7):1129-1139. doi: 10.1158/2767-9764.CRC-25-0091.
5
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.REGAL研究：galinpepimut-S与最佳可用疗法作为急性髓系白血病第二次缓解期维持治疗的比较。
Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28.
6
[Clinical Characteristics and Prognostic Analysis of Newly Diagnosed Acute Myeloid Leukemia Patients with and Gene Mutations].[初诊急性髓系白血病伴 和 基因突变患者的临床特征及预后分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):682-690. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.009.
7
Associated Familial Acute Myeloid Leukemia (AML)伴发的家族性急性髓系白血病（AML）
8
The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety.CPX-351在急性髓系白血病治疗格局中的作用：作用机制、疗效与安全性
Drugs. 2025 May 10. doi: 10.1007/s40265-025-02194-w.
9
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.维奈托克联合去甲基化药物用于急性髓系白血病诱导治疗的疗效及预后分析：一项关于适应证特异性分层、分子标志物和血液学毒性的多中心真实世界研究
Cancer Cell Int. 2025 Jul 1;25(1):241. doi: 10.1186/s12935-025-03858-z.
10
[Expression and Prognostic Significance of in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia].[ 在初诊成人急性髓系白血病患者中的表达及预后意义] （原文中此处有缺失内容）
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Jun;33(3):733-737. doi: 10.19746/j.cnki.issn.1009-2137.2025.03.016.

引用本文的文献

1
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.AML60+评分对接受去甲基化药物治疗的老年急性髓系白血病患者的预后影响：一项回顾性多中心分析
Cancers (Basel). 2025 Aug 14;17(16):2658. doi: 10.3390/cancers17162658.

本文引用的文献

1
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.各年龄段急性髓系白血病患者的靶向性基因异常。
Am J Hematol. 2024 Apr;99(4):792-796. doi: 10.1002/ajh.27236. Epub 2024 Feb 15.
2
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML.新诊断为 AML 的老年和年轻患者中存在骨髓增生异常相关突变提示预后不良。
Blood Cancer J. 2023 Jan 4;13(1):4. doi: 10.1038/s41408-022-00774-7.
3
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
4
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
5
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.对接受强化化疗实现长期生存的 60 岁以上 AML 患者进行遗传学鉴定。
Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103.
6
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.采用前瞻性基因组分析的急性髓细胞白血病精准医学治疗：Beat AML 主试验的可行性和初步疗效。
Nat Med. 2020 Dec;26(12):1852-1858. doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26.
7
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.老年人急性髓系白血病的遗传学：75 岁或以上强化治疗患者的突变谱和临床影响。
Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.
8
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.儿童急性髓系白血病的分子特征揭示了反复出现的结构改变和年龄特异性的突变相互作用。
Nat Med. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439. Epub 2017 Dec 11.
9
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.老年急性髓系白血病具有独特的基因和表观遗传特征。
Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3.
10
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.急性髓系白血病驱动基因突变的频谱及预后相关性。
Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. Epub 2016 Jun 10.